Download App

Log in to access Online Inquiry
Company Overview More
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; and Viome. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
CEO: Walmsley, Emma N.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

GSK GlaxoSmithKline
44.970-0.030-0.07%
Post Mkt Price
44.97000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
190.16% 13.98B -32.98% 4.14B -31.95% 4.34B -19.51% 3.51B
-Cash and cash equivalents
130.54% 10.97B -33.13% 4.07B -32.07% 4.27B -19.38% 3.45B
-Short-term investments
4916.67% 3.01B -21.79% 61M -21.79% 61M -26.51% 61M
-Accounts receivable
27.85% 8.3B 12.56% 6.25B 13.06% 7.86B -2% 7.7B
-Taxes receivable
-28.08% 497M -27.57% 486M -27.57% 486M 3.53% 587M
-Other receivables
-- -- 24.43% 1.3B -- -- -- --
Inventory
-3.43% 6B -3.55% 5.78B -3.55% 5.78B -3.04% 6.24B
Prepaid assets
-- -- -12.26% 315M -- -- -- --
Restricted cash
-- -- 0% 200M -- -- -- --
Total current assets
56.49% 28.99B -7.77% 18.67B -7.77% 18.67B -8.18% 18.25B
Non current assets
Net PPE
0.67% 10.7B -3.03% 10.67B -3.03% 10.67B -4.8% 10.67B
-Gross PPE
0.67% 10.7B -3.56% 21.52B -3.03% 10.67B -4.8% 10.67B
-Accumulated depreciation
-- -- 4.08% -10.85B -- -- -- --
Goodwill and other intangible assets
3.29% 41.17B 0.52% 40.63B 0.52% 40.63B -1.75% 40.82B
-Goodwill
2.52% 10.71B -0.42% 10.55B -0.42% 10.55B -2.81% 10.58B
-Other intangible assets
3.57% 30.47B 0.86% 30.08B 0.86% 30.08B -1.38% 30.24B
Financial assets
166.67% 16M 260% 18M 260% 18M 50% 6M
Defined pension benefit
-- -- 304.92% 741M -- -- -- --
Other non current assets
82.61% 1.81B -- -- 61% 1.68B 33.58% 1.25B
Total non current assets
1.92% 60.7B 0.41% 60.43B 0.41% 60.43B -1% 60.44B
Total assets
14.87% 89.69B -1.65% 79.1B -1.65% 79.1B -2.77% 78.69B
Liabilities
Current liabilities
Payables
20.24% 18.36B 4.1% 5.69B 10.12% 18.04B 2.42% 15.95B
-accounts payable
20.31% 17.58B 4.09% 4.54B 10.82% 17.55B 0.58% 15.23B
-Total tax payable
18.64% 783M -10.28% 489M -10.28% 489M 67.52% 717M
-Other payable
-- -- 17.96% 670M -- -- -- --
Current provisions
-19.51% 693M -20.06% 841M -20.06% 841M -8.84% 722M
Current debt and capital lease obligation
29.32% 4.1B -3.33% 3.6B -3.33% 3.6B -0.92% 4.87B
-Current debt
-- -- -2.78% 3.4B -- -- -- --
-Current capital lease obligation
-- -- -11.74% 203M -- -- -- --
Other current liabilities
30.16% 971M 25.23% 958M 25.23% 958M -1.42% 765M
Current liabilities
19.74% 24.28B 6.87% 23.67B 6.87% 23.67B 1.07% 22.42B
Non current liabilities
Long term provisions
-4.32% 643M -10.89% 630M -10.89% 630M -12.15% 687M
Long term debt and capital lease obligation
26.81% 29.23B -12.18% 20.57B -12.18% 20.57B -11.13% 20.74B
-Long term debt
-- -- -12.33% 19.76B -- -- -- --
-Long term capital lease obligation
-- -- -8.46% 812M -- -- -- --
Non current accrued expenses
-- -- -68.29% 13M -- -- -- --
Derivative product liabilities
15% 23M -90% 1M -90% 1M -83.33% 1M
Other non current liabilities
4.26% 6.1B 0.27% 5.12B 2.23% 6.04B -4.02% 5.87B
Total non current liabilities
16.27% 42.78B -9.03% 34.09B -9.03% 34.09B -9.44% 34.52B
Total liabilities
17.5% 67.06B -3.12% 57.76B -3.12% 57.76B -5.57% 56.94B
Shareholders'equity
Share capital
0.07% 1.35B 0.07% 1.35B 0.07% 1.35B 0.07% 1.35B
-common stock
0.07% 1.35B 0.07% 1.35B 0.07% 1.35B 0.07% 1.35B
Retained earnings
43.84% 9.64B 17.6% 7.94B 17.6% 7.94B 10.32% 7.78B
Paid-in capital
4.25% 3.44B 0.61% 3.3B 0.61% 3.3B 0.61% 3.3B
Other equity interest
-- -- -- -28M -- -- -- --
Total stockholders'equity
8.85% 16.18B 3.21% 15.06B 3.21% 15.06B 7.98% 15.43B
Noncontrolling interests
4.98% 6.45B 1.06% 6.29B 1.06% 6.29B -0.27% 6.32B
Total equity
7.72% 22.63B 2.57% 21.34B 2.57% 21.34B 5.44% 21.75B
Currency Unit
GBPGBPGBPGBP
Accounting Standards
NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%